回复 1楼honeymustard的帖子 华人上的大妈是不是都是中专毕业或者就是文盲?!或者就是人云亦云?还是都是某功某毒的? 英文哪里写了中国试验黄了?中国有两个实验,一个是severe一个是moderate,都是4月揭盲,由中国的试验者写数据。药厂目前不知道情况,但只是听说severe那个因为实验人数不涨提前结束了。这不代表没拿到数据。5月份还有两个实验揭盲,包括Gilead自家但那个。 一群无知大妈只会人云亦云,咋咋唬唬,居然能够把这么正面的公开信给颠倒是非。 哪里黄了?靠 We expect that we will have preliminary data from the study of remdesivir in severe patients at the end of April and will work quickly to interpret and share the findings. The publication of data from the China remdesivir trials rests with the Chinese investigators, but we have been informed that the study in patients with severe symptoms was stopped due to stalled enrollment. We look forward to reviewing the published data when available. In May, we anticipate the initial data from the placebo-controlled NIAID trial as well as data from the Gilead study of patients with moderate symptoms of COVID-19.
你懂英文吗?!信里面哪里写了效果一般?! 这么恶毒的带节奏,昨天也是一样,明明是媒体报道同情用药显示瑞德西韦有奇效,居然某大妈发帖说是此药无效,一群人上来说这是无效。今天华尔街日报头版登人民的希望显示初步有效 前天是把药扩大实验人数,也是一群人上来说表明失败了,失败了还扩大实验人数?真是无知 一群中专生英语盲的网站! We expect that we will have preliminary data from the study of remdesivir in severe patients at the end of April and will work quickly to interpret and share the findings. The publication of data from the China remdesivir trials rests with the Chinese investigators, but we have been informed that the study in patients with severe symptoms was stopped due to stalled enrollment. We look forward to reviewing the published data when available. In May, we anticipate the initial data from the placebo-controlled NIAID trial as well as data from the Gilead study of patients with moderate symptoms of COVID-19.
国内的重症效果一般;所有针对重症的实验,昨天已经停了。 轻症国内的伙食好点,自愈也很高。
但是,这个可能比较适合,医疗系统濒临奔溃的国家。像意大利,西班牙,法国这些国家可以多扩大测试。
The publication of data from the China remdesivir trials rests with the Chinese investigators, but we have been informed that the study in patients with severe symptoms was stopped due to stalled enrollment
We expect that we will have preliminary data from the study of remdesivir in severe patients at the end of April and will work quickly to interpret and share the findings. The publication of data from the China remdesivir trials rests with the Chinese investigators, but we have been informed that the study in patients with severe symptoms was stopped due to stalled enrollment. We look forward to reviewing the published data when available. In May, we anticipate the initial data from the placebo-controlled NIAID trial as well as data from the Gilead study of patients with moderate symptoms of COVID-19.
We expect that we will have preliminary data from the study of remdesivir in severe patients at the end of April and will work quickly to interpret and share the findings. The publication of data from the China remdesivir trials rests with the Chinese investigators, but we have been informed that the study in patients with severe symptoms was stopped due to stalled enrollment. We look forward to reviewing the published data when available. In May, we anticipate the initial data from the placebo-controlled NIAID trial as well as data from the Gilead study of patients with moderate symptoms of COVID-19.
dukenyc125 发表于 4/11/2020 2:58:56 PM
你看上下文,preliminary data 是gilead 自己的trial, 中国的终止了数据等文章,nih的5月给结果。
都在美国工作过吗?声明里面的愤怒都遮不住了,还没指责哪?你们都这么解读工作email的吗?是不是非得说搬起石头,玩火自焚,严重警告,言之不预才能明白是指责? 我翻译一下: The data rest with the Chinese investigators, AKA, They refuse to share the data. We look forward to review the published data when available, AKA, for this study, We know as much information as general public, and we may not agree with the conclusion and interpretation in the paper. 现在看懂了吗? ConnieBear 发表于 4/11/2020 1:57:00 PM
The publication of data from the China remdesivir trials rests with the Chinese investigators, but we have been informed that the study in patients with severe symptoms was stopped due to stalled enrollment. We look forward to reviewing the published data when available. 听着像重症那边trial废了,然后其他data到现在都没拿到,也就谈不上有没有用了。
The publication of data from the China remdesivir trials rests with the Chinese investigators, but we have been informed that the study in patients with severe symptoms was stopped due to stalled enrollment. 这个简直是必然的,中国显然不能指望了。不过我也没想到中国方面可以把事情做得这么难看。幸好还有别的试验在进行。 coalpilerd 发表于 4/11/2020 10:47:07 AM
跟remdesivir相关的临床试验sponsor并不都是Gilead啊。 Gilead自己公司的三期临床试验在全球展开。中国的remdesivir双盲实验sponsor是首都医科大学,曹彬是pi。美国National Institute of Allergy and Infectious Diseases (NIAID)也在做二期临床。法国INSERM in France has initiated a study evaluating remdesivir and other potential treatments, using a master protocol developed by WHO. Gilead 给这三个trial提供study drug at no charge and provided input on study design and conduct. 除了gilead自己的全球三期临床试验,其他这些都是independent的研究(investigator sponsored trial)。作为IST,用Gilead公司的药,应该是需要申请Gilead的批准同意,study design,protocol,并且跟踪study进展的。 采集分析数据是investigator的responsibility。作为IST,PI share publication不是mandated。share report或者publication都应该是在trial开始前就应该是和gilead讲好了的。
The friendly american people gave Chinese people medicine to save lives. These shameless bastards registered patent ahead of Gilead ! Shameless... 天河水 发表于 4/11/2020 7:26:28 PM
The publication of data from the China remdesivir trials rests with the Chinese investigators, but we have been informed that the study in patients with severe symptoms was stopped due to stalled enrollment. We look forward to reviewing the published data when available. 对这段话有不同的解读,看出问题的自然觉得有问题,岁月静好的继续洗。
你不会断句?
所以都是volunteer。。。。。。,有人是愿意为社会做贡献的。再换句话说,对好多clinical trial 来说,吃药的组不见得比吃安慰剂的组安全,有些药不但不起作用还会有严重的副作用。愿意参加的人都是值得尊敬的。你的愿望是假设医生给你的药要不起作用要不不起作用,没有假设药可能会有坏的影响。所以才会有这样的结论。大多数中国人也都是这样想的。可是美国人不是。
顶上去
你看上下文,preliminary data 是gilead 自己的trial, 中国的终止了数据等文章,nih的5月给结果。
Re
再傻也看出来了。太恶心了。
本来在中国做Trial就不多,这次紧急情况搞成这样,以后确实大家都要警惕了。
中国是最早有大量病人的地方。当时想在其他国家做也没得可做。
早看出来了
没有。。中国貌似越来越遥远
这几个id我都背下来了,实在太明显了,都想列个单子出来了
标题党。中国没病人了还怎么继续?
支持列单子,可以避免踩雷
没法愤怒啊,这公司目前很大部分的收入来自中国乙肝病人用药,要是和中国政府闹翻了,中国不用他家药,那股票马上跌成纸
???中国政府真牛逼!中国政府手握9000万乙肝患者人质,你美国公司敢不低头!
是,留心一下就知道那几只是带任务的wm外宣
单子早就有人开过了。那些id也早就暴露过好几轮了,可惜的是,华人上有那么一群人,就是不承认有网评员,不承认有大外宣在故意散播虚假消息,不知道是真瞎还是装瞎。
不要泛政治化,现在这个论坛的气氛很不好,什么事都要动不动上纲上线,几派互斗,帽子乱飞。谁都希望特效药赶快出来,不明白为什么对科学研究医疗治疗的事,去反复揣测背后的政治势力阴谋角逐。
啥也不懂瞎说。什么叫双盲都不知道,谁告诉你对照组是安慰剂?
它们有超版背书的。感觉现在的华人后台们既想要美华大妈们的流量,又想向大外宣表白
这个不是新闻啊,一开始就有很多新闻,重症的招不到人,当时美国的关于clinical trial的网站上也显示了才找了20多个。后来找了多少不知道,但是这玩意感觉国内的病人不想试,毕竟重症的治疗还不错。轻中症的实验还在继续,还没到揭盲的日子
一群人纯有病。专利信息都是公开的,制作方法也不是机密。又不是中国垄断了别人就制造部了了。你们去查查新闻,台湾早就会制造了
别扯淡了,wm能不能稍微提高一下业务水平啊。没听说过PI直接公布数据的,都是第三方揭盲审核。。。非randomized小trial 有时候sponsor直接收集整理数据。所以你丫搞清楚了,PI从来不直接公布数据,每个PI都只是招募一部分病人,数据缺乏totality. 但PI有义务必须提供自己病人的数据点。懂了吗wm兄,以后开展工作的时候接着用上给你科普的这些知识:)
这个wm水平就更拉稀了。。。
翻了好几页才终于看到一个理性且会读原文的。现在华人网都是什么货色可想而知。
正解。
🙏
Pfizer 有进入clinic trial 的药了。也在做疫苗。wsj报告了
你该读读评论
谁在讨论那53个。那53个和中国毛关系没有。 我们讨论的是在中国参加了clinical trial 的人的数据。 二月份的时候,就有报道,当时中国就已经有200个重症参与了clinical trial。 重症哦。 结果现在快两个月了,中国那边就一句重症trial人不够,停了。那已经trial的200多人的数据呢? 就不给了? 这么流氓,不该骂???
数据数据数据。 你数据分享给gilead,有什么难的? 和hypothesis成不成立有个什么关系? 难道和合作伙伴分享数据的前提是 hypothesis 必须成立么? 我还不知道有这么荒唐的前提。
看看covid-19爆发以来,多少文章只有几个人的数据,都可以大大方方发文章分享。更不用说,gilead是国内trial的partner, 国内和gilead分享数据不是应该的么。
你没看漏啥。这楼里开喷的人不需要看懂。
你引用原文里说的很清楚,重症试验的计划人数是452人,文章说当时involve 了200人,注意不是enrol了,如果只是screen的话,还有相当一部分会screen fail。即使这200个都enroll 了,才不到一半预计人数。这之后疫情慢慢得到控制,可选重症病人越来越少。临川试验招病人有inclusion/exclusion criteria, 不是来了就收,国内很多重症病人都用了乱七八糟的药,不见得符合标准。即使符合标准,也有人不会愿意承受分到对照组的风险。因为试验设计疾病特点竞争药品问世等各种原因导致enrollment delay 太常见了,只不过在流行性疾病上还有时效问题,delay就意味着招不够。做过临床试验的人都见怪不怪,更不会当个宝扯到政治上去。
提早结束enroll不够都不是主要的糟点,大家喷的是不分享preliminary data.你做过临床实验的话,药厂提供药物提供protocol,你做完了叫药厂等你文章看数据吗?你文章不跟药厂clear就发吗?
你确定在这个楼里那些人主要喷的是这一点吗?
不少人说中国政府害人性命,有心让这个实验失败,我完全看不出这个攻击和你说的这一点有什么关系。
还是那句话:这里的一堆人逢中就反,本质和国内逢美就骂的五毛们没有任何区别。
嗯,坑了Gilead不说,浪费了全世界的时间。
数据原则上归sponsor。这个trial的sponsor是谁我没研究。再说你说啥不是槽点就不是槽点了么?前面一堆喷不让做完trial的你没看见啊。